Preparation of C-pyrazine-methylamines

Information

  • Patent Grant
  • 8513415
  • Patent Number
    8,513,415
  • Date Filed
    Monday, April 19, 2010
    14 years ago
  • Date Issued
    Tuesday, August 20, 2013
    11 years ago
Abstract
A process for preparing a compound of formula (I) or a salt thereof: (I) wherein R1 is H or optionally substituted aryl or heteroaryl; comprising reacting 2,3-dichloropyrazine with a suitable diaryl imine followed by hydrolysis.
Description
BACKGROUND

The present invention relates to a process for the preparation of C-pyrazine-methylamine compounds, and their conversion to 1,3-substituted-imidazo[1,5-a]pyrazines.


US 2006/0235031 discloses the preparation of C-pyrazine-methylamine compounds, which is different from the process of preparation according to the present invention. The process described in the above-identified application while suitable for the synthesis of small quantities is not ideal for large scale manufacture. Furthermore, the stability of the intermediates from the process in the above-identified publication also needs to be improved. See also U.S. Pat. No. 7,232,911.


There is desire for alternative and improved processes for the preparation of C-pyrazine-methylamine compounds, and their conversion to 1,3-substituted-imidazo[1,5-a]pyrazines with improved scalability, selectivity, efficiency, safety, reduced contamination, and cost.


SUMMARY

The present invention relates to a process for the preparation of C-pyrazine-methylamine compounds. In some aspects, the invention relates to a process for preparing C-pyrazin-2-ylmethylamine compounds of formula (I) or salts thereof:




embedded image


wherein R1 is H or a substituent such as CN, a carboxylate, or an optionally substituted aryl or a heteroaryl group, by reaction of an appropriate arylimine with a dihalopyrazine, followed by hydrolysis. Another aspect of the invention relates to a process for preparing 1,3-substituted imidazo[1,5-a]pyrazine compounds from a compound of formula I.







DETAILED DESCRIPTION

In some aspects of the invention, there is provided a process for preparing a compound of formula (I) or a salt thereof:




embedded image


wherein R1 is H, CN, a carboxylate, or optionally substituted aryl or heteroaryl; comprising reacting a 2,3-dihalopyrazine such as 2,3-dichloropyrazine with a suitable diaryl imine followed by hydrolysis.


In some aspects of the invention, R1 is aryl or heteroaryl, either of which is optionally substituted, such as by aryl, heteroaryl, C1-C10alkyl, C0-C10alkoxy, halo, or cyano.


In some aspects, the process provides compounds of formula I wherein R1 is aryl or heteroaryl;


In some embodiments, in Step (a) the diaryl imine is prepared by Reaction A:




embedded image


or by Reaction B:




embedded image


In some embodiments, in Step (b) the diaryl imine product of (a) and the 2,3-dichloropyrazine are reacted together in the presence of base; and in some embodiments in Step (c) the product of (b) is hydrolyzed to obtain the compound of formula I. In some embodiments, Reaction B is used to prepare the diaryl imine.


In some embodiments, R1 is an aryl group selected from phenyl, 4-chlorophenyl, 4-fluorophenyl, 4-bromophenyl, 3-nitrophenyl, 2-methoxyphenyl, 2-methylphenyl, 3-methyphenyl, 4-methylphenyl, 4-ethylphenyl, 2-methyl-3-methoxyphenyl, 2,4-dibromophenyl, 3,5-difluorophenyl, 3,5-dimethylphenyl, 2,4,6-trichlorophenyl, 4-methoxyphenyl, naphthyl, 2-chloronaphthyl, 2,4-dimethoxyphenyl, 4-(trifluoromethyl)phenyl, or, 2-iodo-4-methylphenyl; and the aryl group is optionally substituted with one or more independent substituents selected from C1-C10alkyl, halo, cyano, hydroxy, or phenyl.


In some embodiments, R1 is a heteroaryl group selected from 2-, 3- or 4-pyridinyl, pyrazinyl, 2-, 4-, or 5-pyrimidinyl, pyridazinyl, triazolyl, tetrazolyl, imidazolyl, 2- or 3-thienyl, 2- or 3-furyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzimidazolyl, benzotriazolyl, benzofuranyl, or benzothienyl; and the heteroaryl group is optionally substituted with one or more independent substituents selected from C1-C10alkyl, halo, cyano, hydroxy, or phenyl.


In some embodiments, R1 is 2-phenylquinoline.


In some embodiments, at least about 0.5 mol of formula I is obtained in an overall yield for the process of at least about 50%.


In some embodiments, the reaction solvent for (a) comprises THF or 1,4-dioxane.


In some embodiments according to Reaction B of Step (a), a diphenylmethylamine and an aryl aldehyde can be treated in a suitable solvent at a suitable reaction temperature. Suitable solvents include ethers such as THF, glyme, and the like, CH3CN, chlorinated solvents such as CH2Cl2 or CHCl3, and esters such as EtOAc and the like, and mixtures thereof. Preferred solvents include THF and EtOAc. The reaction can be carried out at about 0° C. to about 120° C., preferably, about 25° C. to about 80° C. The reaction can be carried out at about atmospheric pressure although higher or lower pressures can be used. In some embodiments, approximately equimolar amounts of reactants can be used although higher or lower amounts can be used.


In some embodiments, Reaction A is carried out in the presence of an organic base and a Lewis acid. In some embodiments, the organic base in Reaction A comprises Et3N or NMM. In some embodiments, the Lewis acid comprises TiCl4. Suitable solvents include ethers such as THF, glyme, and the like, CH3CN; and chlorinated solvents such as CH2Cl2 or CHCl3 and mixtures thereof. Preferred solvents include THF and 1,4-dioxane. The reaction can be carried out at about −78° C. to about 120° C., preferably, about −78° C. to about 20° C. The reaction can be carried out at about atmospheric pressure although higher or lower pressures can be used. In some embodiments, approximately equimolar amounts of reactants can be used although higher or lower amounts can be used.


In some embodiments, the reaction (b) of the diaryl imine with 2,3-dichloropyrazine is carried out in the presence of a metal hexamethyl disilazide, a metal amide, a metal hydride, a hindered alkoxide such as a tert-butoxide or tert-pentoxide, a metal carbonate or an organic base such as DBU.


In some embodiments of reaction Step (b), 2,3-dichloropyrazine and a (diphenylmethylidene)methanamine compound can be treated with a base in a suitable solvent at a suitable reaction temperature. Suitable solvents for use in the reaction include ethers such as THF, glyme, 1,4-dioxane and the like, and mixtures thereof. Preferred solvents include THF. Suitable bases include HMDS sodium salt or potassium tert-butoxide. The reaction can be carried out at about −78° C. to about 50° C., preferably about −20° C. to about 25° C. The reaction can be carried out at about atmospheric pressure although higher or lower pressures can be used. In some embodiments, approximately equimolar amounts of reactants can be used although higher or lower amounts can be used.


In a typical preparation according to Step (c), a 1-(3-chloropyrazin-2-yl)-N-(diphenylmethylidene)methanamine compound is treated with an acid, in a suitable solvent at a suitable reaction temperature. Suitable acids include HCl, sulfuric acid, or TFA. Suitable solvents for use in the reaction include ethers such as THF, glyme, and the like, esters such as EtOAc and the like, CH3CN, chlorinated solvents such as CH2Cl2 or CHCl3, toluene, or HCl in MeOH. If desired, mixtures of these solvents can be used. Preferred solvents include CH2Cl2, EtOAc, THF and toluene. The reaction can be carried out at about −40° C. to about 60° C., preferably, about 0° C. to about 40° C. The reaction can be carried out at about atmospheric pressure although higher or lower pressures can be used. In some embodiments, approximately equimolar amounts of reactants can be used although higher or lower amounts can be used.


In some embodiments, in Step (a) the diaryl imine is prepared by Reaction C:




embedded image


wherein R2 is C1-C10alkyl; (b) the diaryl imine product of (a) and the 2,3-dichloropyrazine are reacted together in the presence of base; and (c) the product of (b) is hydrolyzed to obtain the compound of formula I wherein R1 is H.


In some embodiments, R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, n-heptyl, isooctyl, nonyl, decyl, any of which can be substituted by one or more independent substituents selected from C1-C10alkyl, halo, cyano, hydroxy, or phenyl. In some embodiments, R2 is methyl.


In some embodiments, at least about 0.5 mol of formula I is obtained in an overall yield for the process of at least about 50%.


In some embodiments, Reaction C is carried out in the presence of DIEA or Et3N.


In some embodiments, the base for (b) comprises potassium carbonate or cesium carbonate.


In some embodiments, (c) is carried out in the presence of potassium hydroxide, sodium hydroxide, or lithium hydroxide. In some embodiments, (c) is carried out in the presence of HCl, TFA, acetic acid, or sulfuric acid.


In some embodiments, an advantage of this process is that (3-chloropyrazin-2-yl)methanamine can be made without resorting to the formation of halomethyl pyrazine which is lacrymatory and difficult to form selectively.


In some embodiments of Reaction C, benzophenone can be reacted with a glycine alkyl ester in a suitable solvent at a suitable reaction temperature in the presence of a base. Suitable solvents for use in the reaction included THF, glyme, and the like, propionitrile, acetonitrile, nonpolar solvents such as toluene, and chlorinated solvents such as CH2Cl2 or CHCl3, or solvent mixtures. A preferred solvent is toluene. The reaction can be carried out at about −20° C. to about 120° C., preferably about 20° C. to about 120° C. Bases such as DIEA or Et3N can be used. The reaction can be carried out at about atmospheric pressure although higher or lower pressures can be used. In some embodiments, approximately equimolar amounts of reactants can be used although higher or lower amounts can be used.


In some embodiments, the resulting glycine benzophenone imine compound can be reacted with 2,3-dichloropyrazine in a suitable solvent at a suitable temperature. Suitable solvents for use in the above process include THF, glyme, and the like, DMF, DMSO, propionitrile, Et3N, nonpolar solvents such as toluene, and chlorinated solvents such as CH2Cl2 or CHCl3, or solvent mixtures. A preferred solvent is DMF. The reaction can be carried out at about −20° C. to about 130° C., preferably, about 20° C. to about 130° C. Bases such as potassium carbonate, cesium carbonate, DBU, or other bases can be used. The reaction can be carried out at about atmospheric pressure although higher or lower pressures can be used. In some embodiments, approximately equimolar amounts of reactants can be used although higher or lower amounts can be used.


In some embodiments, the resulting alkyl 2-(3-chloropyrazin-2-yl)-2-(diphenylmethylideneamino)acetate compound can be hydrolyzed in a suitable acid and/or a suitable base at a suitable reaction temperature. Suitable acids for use in the above process include HCl, TFA, acetic acid, and sulfuric acid. A preferred acid is HCl. Suitable bases include potassium hydroxide, sodium hydroxide, and lithium hydroxide. A preferred base is sodium hydroxide. Suitable solvents include water; nonpolar solvents such as toluene, alcohols, ethers such as THF, and chlorinated solvents such as CH2Cl2 or CHCl3, or solvent mixtures. A preferred solvent is toluene. The reaction can be carried out at about −20° C. to about 80° C., preferably, about 20° C. to about 50° C. The reaction can be carried out at about atmospheric pressure although higher or lower pressures can be used. In some embodiments, approximately equimolar amounts of reactants can be used although higher or lower amounts can be used.


In some embodiments, the process further comprises reacting the compound of formula I according to the reactions:




embedded image


wherein R3 is C1-C10alkyl, C3-C12cycloalkyl, aryl, or heteroaryl, any of which is optionally substituted by one or more independent substituents selected from halo, oxo, cyano, hydroxy, and C1-C10alkyl; and R4 is hydroxy, alkoxy, chloro, or imidazole.


In some embodiments, the process further comprises the reactions:




embedded image


In some embodiments of the preparation of a compound of Formula (IV), a compound of formula (I) and a compound of Formula (III) are reacted under suitable amide coupling conditions. Suitable conditions include treating compounds of Formula (I) and (III) (when R4═OH) with coupling reagents such as DCC or EDC in conjunction with DMAP, HOBt, HOAt and the like. Suitable solvents include ethers such as tetrahydrofuran THF, glyme, and the like, DMF, DMSO, CH3CN, EtOAc, or halogenated solvents such as CHCl3 or CH2Cl2, and solvent mixtures. Preferred solvents include CH2Cl2 and DMF. The process can be carried out at about 0° C. to about 80° C., preferably about room temperature (rt). The reaction can be carried out at about atmospheric pressure although higher or lower pressures can be used. In some embodiments, approximately equimolar amounts of reactants can be used although higher or lower amounts can be used.


In some embodiments, compounds of Formula (I) and (III) (where R4═Cl, Br, I) can be reacted with bases such as Et3N or DIEA or the like optionally in conjunction with DMAP or the like. Suitable solvents include ethers such as THF, glyme, and the like, DMF, CH3CN, EtOAc, halogenated solvents such as CH2Cl2 or CHCl3, or mixtures thereof. A preferred solvent is CH2Cl2. The process can be carried out at about −20° C. to about 40° C., preferably about 0° C. to about 25° C. The reaction can be carried out at about atmospheric pressure although higher or lower pressures can be used. In some embodiments, approximately equimolar amounts of reactants can be used although higher or lower amounts can be used. In some embodiments, substantially equimolar amounts of compounds of Formula (I) and (III) (where R4═Cl, Br, I) and base and substoichiometric amounts of DMAP can be used. Other suitable reaction conditions for the conversion of a compound of Formula (I) to a compound of Formula (IV) can be found in Larock, R. C. Comprehensive Organic Transformations, 2nd ed.; Wiley and Sons: New York, 1999, pp 1941-1949.


In some embodiments of the preparation of a compound of formula (V), an intermediate of Formula (IV) can be treated with POCl3, with or without a suitable solvent at a suitable reaction temperature. Suitable solvents include ethers such as THF, glyme, DMF, EtOAc, and the like, CH3CN, and chlorinated solvents such as CH2Cl2 or CHCl3, or mixtures of solvents. Preferred solvents include CH3CN; DMF, and CH2Cl2. The above process can be carried out at about 0° C. to about 120° C., preferably about 20° C. to about 95° C. The reaction can be carried out at about atmospheric pressure although higher or lower pressures can be used. In some embodiments, approximately equimolar amounts of reactants can be used although higher or lower amounts can be used.


All processes of preparation, as described above, are supplemented by synthetic methods known in the art of organic chemistry, or modifications and derivatizations that are familiar to those of ordinary skill in the art. The starting materials used herein are commercially available or may be prepared by routine methods known in the art.


EXAMPLES
Example 1
N-[bis(4-methoxyphenyl)methylidene]-1-(2-phenylquinolin-7-yl)methanamine



embedded image


C-(2-Phenylquinolin-7-yl)methylamine (170 mg, 0.73 mmol) and 4,4′-dimethoxybenzophenone (176 mg, 0.73 mmol) were added to a flask under nitrogen. THF (4 mL) and triethylamine (0.30 mL, 2.2 mmol) were then added. The mixture was cooled to −78° C. and titanium tetrachloride (0.080 mL, 0.73 mmol) was added. The reaction mixture was allowed to warm to room temperature. After stirring for 30 minutes the mixture was cooled to −78° C. and triethylamine (2 mL) was added followed by water (3 mL). The mixture was warmed to room temperature and DCM was added. The organic solution was washed with water, dried over sodium sulfate, filtered, and concentrated to dryness in vacuo. The resultant yellow oil was purified by silica gel chromatography (eluted with DCM/heptane 2:1). A light yellow solid (0.247 g, yield 74%) was obtained.



1H NMR (400 MHz, CDCl3) δ ppm 3.83 (s, 3H), 3.87 (s, 3H), 4.83 (s, 2H), 6.83-6.91 (m, 2H), 6.94-7.03 (m, 2H), 7.14-7.22 (m, 2H), 7.40-7.58 (m, 4H), 7.65-7.74 (m, 2H), 7.75-7.87 (m, 2H), 8.07-8.23 (m, 4H). Reference: N. Sotomayor Tetrahedron, 1994, 50, 2207


Example 2
C-(3-chloropyrazin-2-yl)-C-(2-phenylquinolin-7-yl)methylamine



embedded image


N-[bis(4-methoxyphenyl)methylidene]-1-(2-phenylquinolin-7-yl)methanamine (100 mg, 0.22 mmol) was added to a flask and protected by nitrogen. THF (2 mL) was added and a clear solution was obtained. The solution was cooled to −5° C. and then 1.0 M 1,1,1,3,3,3-hexamethyldisilazane, sodium salt in THF (0.26 mL, 0.26 mol) was added. After 20 min, 2,3-dichloropyrazine (36 mg, 0.24 mmol) in THF (1.0 mL) was added. After a further 20 min, 2M HCl (2 mL) was added and the mixture was stirred at room temperature for 10 min. The aqueous mixture was washed with DCM (3×) and then basified to pH 10 with solid potassium carbonate. A white solid precipitated from the aqueous solution and the resulting suspension was extracted with DCM. The organic solution was washed with water, dried over sodium sulfate, filtered, and concentrated in vacuo to give a light yellow oil (67 mg). The yellow oil was further purified by silica gel chromatography (eluted with ethyl acetate/methanol/triethylamine, 10:0.5:1) to yield a colorless oil (63 mg, 83% yield).


Example 3
1,1-diphenyl-N-((2-phenylquinolin-7-yl)methylene)methanamine



embedded image


7-Bromo-2-phenyl-quinoline (40.0 g, 0.141 mol) was added to a 1000 mL three-neck round bottom flask (rbf). The flask was degassed and filled with N2. THF (400 mL) was added. The solid dissolved. The flask was kept in a cooling bath (at −62° C.). The off-white solid crashed out at low temperature. 1.4 M of sec-butyllithium in cyclohexane (125.7 mL, 0.176 mol) was added within 15 min, and the internal temperature was kept at around −50° C. After addition was complete, the reaction was stirred at −50° C. (internal temperature) for 5 min. DMF (13.6 mL, 0.176 mol) was added within 10 min and the internal temperature was always kept at around −50° C. and the cooling bath was kept at around at −62° C. After 35 min, the reaction was quenched by NH4Cl/water (200 mL), and EtOAc (200 mL) was added. The organic layer was washed with water (300 mL×2) and brine (150 mL), dried over MgSO4, filtered and concentrated in vacuo. After evaporating to almost dryness, EtOAc (200 mL) was added and heated in a 70° C. oil bath to dissolve the solid. Half of the aminodiphenylmethane (26.2 mL, 0.148 mol) was added and the reaction was stirred at 58° C. (internal temperature) for 5 min. The reaction was seeded and the solid came out of solution slowly. After 5 min, the remaining aminodiphenylmethane was added within 3 min. The oil bath temperature was kept at 70° C., the internal temperature increased to 67° C. After 10 min, the reaction mixture was cooled in an ice bath. The off-white solid was collected by vacuum filtration and dried in vacuo at 40-60° C. for 2 hours. The title compound was isolated as an off-white solid (37.42 g, 67% yield).


Example 4
Synthesis of (E)-1,1-diphenyl-N-((2-phenylquinolin-7-yl)methylene)methanamine Via a Different Starting Material from that of Example 3



embedded image


2-Phenylquinoline-7-carbaldehyde (85.00 g, 0.364 mol) and EtOAc (255 mL) were added to a rbf and heated in a 70° C. oil bath. Half of aminodiphenylmethane (70.11 g, 0.38261 mol) was added quickly. After 2 min, a light brown solid precipitated. The reaction was exothermic and the reaction temperature increased to 73° C. The remaining aminodiphenylmethane was then added within 3 min. The reaction temperature decreased to 67° C. slowly. After 30 min, heating was discontinued and the reaction was cooled in an ice bath to about 15° C. The yellow solid was collected by vacuum filtration and dried in vacuo at 45° C. overnight. The title compound was isolated as a yellow solid (115.77 g, 80% yield). 1H NMR (400 MHz, CDCl3) δ ppm 5.69 (s, 1H), 7.21-7.28 (m, 2H), 7.31-7.38 (m, 4H), 7.43-7.50 (m, 5H), 7.50-7.57 (m, 2H), 7.84 (d, J=8.59 Hz, 1H), 7.90 (d, J=8.59 Hz, 1H), 8.13-8.19 (m, 2H), 8.22 (d, J=8.08 Hz, 1H), 8.26 (dd, J=8.46, 1.64 Hz, 1H), 8.37 (s, 1H), 8.65 (s, 1H).


Example 5
Synthesis of (3-chloropyrazin-2-yl)(2-phenylquinolin-7-yl)methanamine



embedded image


Benzhydryl-[1-(2-phenyl-quinolin-7-yl)-meth-(E)-ylidene]-amine (12.50 g, 31.4 mmol) was added to a 500 mL rbf fitted with a thermocouple. The flask was degassed and filled with nitrogen. THF (150 mL) was added and the solid dissolved. The mixture was cooled to −5° C. and 1.0 M of HMDS sodium salt in THF (39.2 mL) was added within 5 min. The temperature increased slightly to −3° C. The blue solution was stirred for 20 min at 0° C. and then 2,3-dichloropyrazine (5.61 g, 37.6 mmol) in THF (10 ml) was added within 3 min. The mixture was stirred for 30 min and then quenched with saturated NH4Cl/water (200 mL). EtOAc (200 mL) was added and the aqueous phase was removed. Toluene can also be used. The organic layer was washed with water (200 mL×2) and brine (200 mL). Concentrated HCl (10 mL) and water (200 mL) were added. The phases were separated and the organic layer was extracted with 0.1 M HCl (30 mL). The aqueous was washed with EtOAc (2×) and then saturated K2CO3 was used to adjust to pH 10. The aqueous solution was extracted with EtOAc (2×) and the combined organics were dried over Na2SO4, filtered, and concentrated in vacuo to a brown oil which solidified upon standing to yield the title compound as a brown solid (9.94 g, 81% yield). 1H NMR (400 MHz, CDCl3) δ ppm 2.30 (br s, 2H), 5.79 (s, 1H), 7.43-7.56 (m, 3H), 7.62 (dd, J=8.46, 1.89 Hz, 1H), 7.81 (d, J=8.34 Hz, 1H), 7.86 (d, J=8.59 Hz, 1H), 8.07 (d, J=1.01 Hz, 1H), 8.10-8.16 (m, 2H), 8.19 (d, J=8.59 Hz, 1H), 8.31 (d, J=2.27 Hz, 1H), 8.60 (d, J=2.53 Hz, 1H). MS (ES+): m/z=347.01/349.03 (100/68) [MH+].


Example 6
Synthesis of HCl salt of (3-chloropyrazin-2-yl)-methylamine



embedded image


A 500 mL, 1-necked rbf equipped with a magnetic stirrer, and a Dean-Stark apparatus with a nitrogen inlet was charged with benzophenone (58.0 g, 0.318 mol), glycine methyl ester hydrochloride (20 g, 0.159 mol) and toluene (100 mL). The resulting white suspension was heated to reflux and DIEA (56 mL, 0.318 mol) was added over three hours using a syringe pump. The resulting pale yellow solution was stirred at reflux for an additional 1 h. Upon reaction completion, the reaction mixture was cooled to rt. The reaction mixture was then washed with water (50 mL). The layers were separated and the organic solution was washed with water (50 mL) and concentrated in vacuo at 35-40° C. to give (Benzhydrylideneamino)-acetic acid methyl ester (82.59 g). In a similar fashion, (benzhydrylideneamino)-acetic acid ethyl ester was prepared.


A 100 mL rbf equipped with a magnetic stirrer, and a nitrogen inlet was charged with benzhydrylidene-amino)-acetic acid ethyl ester (10 g, 36.6 mmol), Cs2CO3 (13.27 g, 40.3 mmol) and DMF (50 mL). To the suspension, 2,3-dichloropyrazine (6.13 g, 40.3 mmol) was added. The resulting pale yellow mixture was stirred and heated to 120-125° C. Alternatively, the reaction can be carried out at about 40-60° C. or about 50° C. The resulting dark solution was stirred for 3 h. Upon reaction completion, the reaction mixture was cooled to it, diluted with toluene (50 mL), and washed with water (50 mL). The layers were separated and the bottom aqueous layer was extracted with toluene (2×30 mL). The combined organic layers were washed with water (2×50 mL). The organic layer was concentrated in vacuo at 35-40° C. to remove part of the toluene. This crude material was be hydrolyzed as follows. Alternatively, the method of Example 7 below can be used.


The resultant crude intermediate in toluene was transferred into a 250 mL round bottomed flask equipped with a magnetic stirrer and a nitrogen inlet. Concentrated HCl (37%, 4.0 g, 40.3 mmol) was added and the reaction was allowed to stir at rt for 3 h. After the completion of the imine hydrolysis, the reaction mixture was diluted with toluene and the layers were separated. The bottom aqueous layer was washed with toluene (2×20 mL).


The resultant aqueous solution was then transferred into a 250 mL round bottomed flask equipped with a magnetic stirrer and a nitrogen inlet. The solution was cooled to 5-10° C. using an ice/water bath and sodium hydroxide (10 N, 7.8 mL, 76.9 mmol) was added and allowed to stir at rt for 1 h. After the completion of the ester hydrolysis, the reaction mixture was cooled to 5-10° C.


Concentrated HCl (37%, 4.0 g, 40.3 mmol, 2.1 eq) was added and the reaction was allowed to stir at rt for 12 h and then at 40-45° C. for 24 hours. After the completion of the decarboxylation, the reaction mixture was assayed by HPLC. Based on the HPLC assay, the yield was 58%. A sample was evaporated in vacuo to yield a brown solid. 1H NMR (400 MHz, DMSO-d6/D2O) 8 ppm 4.33 (s, 2H), 8.52 (s, 1H), 8.68 (s, 1H). MS (ES+): m/z=143.98/146.02 (100/80) [MH+].


Example 7

In an alternative approach for hydrolysis, a 72 L round bottom flask equipped with mechanical stirrer, N2 inlet/outlet and thermometer was charged with solution of crude pyrazine imine compound such as produced in Example 6 above (˜30 L, 29.9 mol) in toluene. Water (12 L,) and concentrated HCl (3.2 L, 32.9 mol) was added and the reaction mixture was stirred at ambient temperature for 3 h (monitored by TLC). The layers were separated and aqueous layer was extracted with toluene (15 L).


The aqueous solution was charged to the same reactor and concentrated HCl (3.2 L, 32.9 mol) was added. The reaction was heated at 60° C. and monitored by TLC. After completion of the reaction (24-30 h) the reaction mixture was cooled to 5 to 10° C. and the pH was adjusted to 10 with 50% aqueous NaOH (7 L) while maintaining the temperature below 10° C.


To the basic mixture (10 to 15° C.), Boc2O (7.2 Kg, 32.9 mol) was added and the reaction mixture was warmed to ambient temperature and stirred for 4 h (monitored by TLC). To the batch MTBE (24 L) was added, stirred for 20 min and the organic layer was separated. The aqueous layer was extracted with MTBE (2×12 L). The combined organic phases were concentrated under reduced pressure to remove approximately half of MTBE and the resulting organic solution was transferred to a 50 L jacketed reactor equipped with mechanical stirrer, N2 inlet/outlet and thermometer. The mixture was cooled to between 5 and 10° C. and 20% HCl in 1,4-dioxane (20 L, 109.6 mol) was added slowly while maintaining the internal temperature below 10° C. The reaction mixture was warmed to ambient temperature and stirred for 4 h. The solids were filtered and washed with MTBE (10 L) and dried in vacuum oven at 40° C. for 6 h to afford the desired compound as a dark brown solid. 1H NMR (400 MHz, DMSO-d6): δ 8.82 (br s, 3H), 8.72 (d, J=2.5 Hz, 1H), 8.54 (d, J=2.3 Hz, 1H), 4.22 (s, 2H).



1H NMR (400 MHz or 300 MHz) spectra were recorded on Bruker or Varian instruments at ambient temperature with TMS or the residual solvent peak as the internal standard. The line positions or multiples are given in ppm (δ) and the coupling constants (J) are given as absolute values in Hertz (Hz). The multiplicities in 1H NMR spectra are abbreviated as follows: s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), m (multiplet), mc (centered multiplet), br or broad (broadened), AA′BB′. Flash chromatography was performed with silica gel (400-230 mesh). Mass-directed HPLC purification of compounds was performed on a Waters system composed of the following: 2767 Sample Manager, 2525 Binary Gradient Module, 600 Controller, 2487 Dual λ Absorbance Detector, Micromass ZQ2000 for ionization, Phenomenex Luna 5μ C18(2) 100 Å 150×21.2 mm 5μ column with mobile phases of 0.01% formic acid acetonitrile (A) and 0.01% formic acid in HPLC water (B), a flow rate of 20 mL/min, and a run time of 13 min. LC-MS data was collected on ZQ2, ZQ3, or HPLC-ACQUITY. ZQ2 is an Agilent 1100 HPLC equipped with a Gilson 215 Liquid Handler, Gilson 819 Injection Module, and Waters Micromass ZQ2000 for ionization. ZQ3 is an Agilent 1100 HPLC equipped with an HP Series 1100 auto injector and Waters Micromass ZQ2000 for ionization. Both systems use the Xterra MS C18, 5μ particle size, 4.6×50 mm with a mobile phase of acetonitrile (A) and 0.01% formic acid in HPLC water (B). All Waters Micromass ZQ2000 instruments utilized electrospray ionization in positive (ES+) or negative (ES−) mode. The Waters Micromass ZQ2000 instruments from ZQ2 and ZQ3 can also utilize atmospheric pressure chemical ionization in positive (AP+) or negative (AP−) mode. The Waters UPLC-ACQUITY system consists of an ACQUITY sample manager attached to ACQUITY SQ MS and ACQUITY PDA detectors. It uses an ACQUITY UPLC BEH® C18 2.1×50 mm 1.7 μm column with a mobile phase of 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B). UV detection is at 254 nm, and the MS utilizes electrospray ionization in positive mode (ES+). All melting points were determined with a MeI-Temp II apparatus and are uncorrected. Elemental analyses were obtained by Atlantic Microlab, Inc., Norcross, Ga.


DEFINITIONS AND ABBREVIATIONS

As used herein, the term “aryl” refers to an all-carbon monocyclic, bicyclic, or polycyclic groups of 6 to 12 carbon atoms having a completely conjugated pi-electron system. Examples of aryl include, but are not limited to, phenyl, 4-chlorophenyl, 4-fluorophenyl, 4-bromophenyl, 3-nitrophenyl, 2-methoxyphenyl, 2-methylphenyl, 3-methyphenyl, 4-methylphenyl, 4-ethylphenyl, 2-methyl-3-methoxyphenyl, 2,4-dibromophenyl, 3,5-difluorophenyl, 3,5-dimethylphenyl, 2,4,6-trichlorophenyl, 4-methoxyphenyl, naphthyl, 2-chloronaphthyl, 2,4-dimethoxyphenyl, 4-(trifluoromethyl)phenyl, and 2-iodo-4-methylphenyl.


The terms “heteroaryl” refer to a monocyclic, bicyclic, or polycyclic group of 5 to 12 ring atoms containing one or more ring heteroatoms selected from N, O, and S, the remaining ring atoms being C, and, in addition, having a completely conjugated pi-electron system. Examples of such heteroaryl rings include, but are not limited to, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, and triazinyl. The terms “heteroaryl” also include heteroaryl rings with fused carbocyclic ring systems that are partially or fully unsaturated, such as a benzene ring, to form a benzofused heteroaryl. For example, benzimidazole, benzoxazole, benzothiazole, benzofuran, quinoline, isoquinoline, quinoxaline, and the like. Furthermore, the terms “heteroaryl” include fused 5-6, 5-5, 6-6 ring systems, optionally possessing one nitrogen atom at a ring junction. Examples of such hetaryl rings include, but are not limited to, pyrrolopyrimidinyl, imidazo[1,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, imidazo[4,5-b]pyridine, pyrrolo[2,1-f][1,2,4]triazinyl, and the like. Heteroaryl groups may be attached to other groups through their carbon atoms or the heteroatom(s), if applicable. For example, pyrrole may be connected at the nitrogen atom or at any of the carbon atoms.


The term “alkyl” means both branched and straight chain alkyl groups. Typical alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, n-heptyl, isooctyl, nonyl, decyl, and the like.


The term “alkoxy” includes both branched and straight chain terminal alkyl groups attached to a bridging oxygen atom. Typical alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy and the like.


The term “halo” refers to fluoro, chloro, bromo, or iodo.


Unless otherwise specified, the term “cycloalkyl” refers to a carbon mono-cyclic, bicyclic, or polycyclic aliphatic ring structure, optionally substituted with for example, alkyl, hydroxy, oxo, and halo, such as cyclopropyl, methylcyclopropyl, cyclobutyl, cyclopentyl, 2-hydroxycyclopentyl, cyclohexyl, 4-chlorocyclohexyl, cycloheptyl, cyclooctyl, and the like.









TABLE 1





Abbreviations
















Bn
Benzyl group


Boc
tert-butoxycarbonyl


BOP
Bis(2-oxo-3-oxazolidinyl)phosphinic


Cbz
Benzyloxycarbonyl


CD3OD
Deuterated methanol


CDCl3
Deuterated chloroform


CDI
1,1′-carbonyldiimidazole


CH2Cl2 or
Methylene chloride


DCM


CHCl3
Chloroform


CH3CN
Acetonitrile


DBN
1,5-diazabicyclo[4.3.0]non-5-ene


DBU
1,8-diazabicyclo[5.4.0]undec-7-ene


DCC
1,3-dicyclohexylcarbodiimide


DEA
Diethylamine


DEPC
Diethyl cyanophosphonate


DIEA
Diisopropylethylamine


DMAP
Dimethylaminopyridine


DMC
2-chloro-1,3-dimethylimidazolinium chloride


DMF
N,N-dimethylformamide


DMSO
Dimethyl sulfoxide


EDC
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride


EDTA
Ethylenediaminetetraacetic acid


EGTA
Ethyleneglycol-bis(β-aminoethyl)-N,N,N′,N′-tetraacetic Acid


ESI
Electrospray Ionization for mass spectrometry


Et3N
Triethylamine


EtOAc
Ethyl acetate


EtOH
Ethanol


Fmoc
Fluorene methyloxycarbonyl


HATU
O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium



hexafluorophosphate


HBTU
O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium



hexafluorophosphate


HCl
Hydrochloric acid


HEPES
4-(2-hydroxyethyl)-1-Piperazineethane sulfonic acid


HMDS
1,1,1,3,3,3-hexamethyldisilazane


HOAt
1-hydroxy-7-azabenzotriazole


HOBt
1-hydroxybenzotriazole hydrate


HRMS
High Resolution Mass Spectroscopy (electrospray ionization



positive scan)


K3PO4
Potassium phosphate


LCMS
Liquid Chromatography - Mass Spectroscopy


LRMS
Low Resolution Mass Spectroscopy


MeOH
methanol


NaH
Sodium hydride


NMM
N-methylmorpholine


NMP
1-methyl-2-pyrrolidinone


NMR
Nuclear Magnetic Resonance


PG
Protecting group


TFA
Trifluoroacetic acid


THF
Tetrahydrofuran


TiCl4
Titanium tetrachloride


TLC
Thin layer chromatography








Claims
  • 1. A compound of the formula I:
  • 2. The compound of claim 1, wherein R1 is —C(O)OCH3 or —C(O)OCH2CH3.
Parent Case Info

This application claims priority of U.S. Appl. No. 61/170,911, filed 20 Apr. 2009, which is incorporated herein by reference in its entirety.

PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/US2010/031547 4/19/2010 WO 00 10/20/2011
Publishing Document Publishing Date Country Kind
WO2010/123792 10/28/2010 WO A
US Referenced Citations (83)
Number Name Date Kind
3840537 Garside Oct 1974 A
5217999 Levitzki Jun 1993 A
5302606 Spada Apr 1994 A
5326905 Dow Jul 1994 A
5397787 Buzzetti Mar 1995 A
5556874 Dobrusin Sep 1996 A
6194439 Dow Feb 2001 B1
6265411 Thomas Jul 2001 B1
6337338 Kozlowski Jan 2002 B1
6362336 Lohmann Mar 2002 B1
6486179 Jirousek et al. Nov 2002 B2
6713474 Hirst Mar 2004 B2
6939874 Harmange Sep 2005 B2
7087602 Thomas Aug 2006 B2
7087613 Norris Aug 2006 B2
7115617 Buchanan Oct 2006 B2
7202243 Hendrix Apr 2007 B2
7232911 Vangelisti Jun 2007 B2
7244733 Hunt Jul 2007 B2
7271262 La Greca Sep 2007 B2
7326699 Capraro Feb 2008 B2
7332497 Hirst Feb 2008 B2
7345038 Bright Mar 2008 B2
7348358 Larsson Mar 2008 B2
7459554 Dong Dec 2008 B2
7534797 Arnold May 2009 B2
7648987 Crew Jan 2010 B2
7820662 Arnold Oct 2010 B2
7915256 Andrews Mar 2011 B2
20020076408 Buchsbaum Jun 2002 A1
20030108545 Rockwell Jun 2003 A1
20030114467 Shakespeare Jun 2003 A1
20030144252 Furr Jul 2003 A1
20030153752 Hirst Aug 2003 A1
20030157104 Waksal Aug 2003 A1
20030175763 Degenhardt Sep 2003 A1
20040014774 Myers et al. Jan 2004 A1
20040052785 Goodman Mar 2004 A1
20040057950 Waksal Mar 2004 A1
20040092546 Wei May 2004 A1
20040102655 Liang et al. May 2004 A1
20040106605 Carboni Jun 2004 A1
20040180911 Capraro Sep 2004 A1
20040209930 Carboni Oct 2004 A1
20040220189 Sun Nov 2004 A1
20050009832 Sun Jan 2005 A1
20050032759 Massimini Feb 2005 A1
20050037999 La Greca Feb 2005 A1
20050054638 Barlaam Mar 2005 A1
20050136063 Wang Jun 2005 A1
20050153966 Gangloff Jul 2005 A1
20050215530 Ryan Sep 2005 A1
20050215564 Stiles Sep 2005 A1
20050271747 Higgins et al. Dec 2005 A1
20050277628 Pfau et al. Dec 2005 A1
20060019957 Crew Jan 2006 A1
20060046977 Nunes Mar 2006 A1
20060069084 Burns Mar 2006 A1
20060084654 Beck Apr 2006 A1
20060154982 Larsson Jul 2006 A1
20060166992 Hendrix Jul 2006 A1
20060235031 Arnold et al. Oct 2006 A1
20070087613 Schumacher Apr 2007 A1
20070112005 Chen May 2007 A1
20070149521 Crew Jun 2007 A1
20070149567 Didiuk Jun 2007 A1
20070202101 Rosen Aug 2007 A1
20070203143 Sheppard Aug 2007 A1
20070238734 Nemecek Oct 2007 A1
20070254883 Crew Nov 2007 A1
20070280928 Buck Dec 2007 A1
20080014200 Arnold Jan 2008 A1
20080139582 Honigberg Jun 2008 A1
20080254040 Stefanic Oct 2008 A1
20080267957 Arnold Oct 2008 A1
20090093488 Buck Apr 2009 A1
20090181940 Beck Jul 2009 A1
20090263397 Buck Oct 2009 A1
20090286768 Crew Nov 2009 A1
20090325928 Arnold Dec 2009 A1
20100286155 Buck Nov 2010 A1
20110046144 Mulvihill Feb 2011 A1
20130005733 Barr Jan 2013 A1
Foreign Referenced Citations (16)
Number Date Country
1 422 220 May 2004 EP
05089352 Apr 2005 JP
9728161 Aug 1997 WO
0112227 Feb 2001 WO
0112604 Feb 2001 WO
0172751 Oct 2001 WO
02079192 Oct 2002 WO
03024967 Mar 2003 WO
03080064 Oct 2003 WO
2006004703 Jan 2006 WO
2006033001 Mar 2006 WO
2008106168 Sep 2008 WO
2009008992 Jan 2009 WO
2010120599 Oct 2010 WO
2011163430 Dec 2011 WO
2012129145 Sep 2012 WO
Non-Patent Literature Citations (105)
Entry
Johnson, J.I.et al. (2001) British Journal of Cancer 84:1424-1431.
Jones, H.E. et al. (2004) Endocr Relat Cancer 11:793-814.
Khalil, M.Y. et al. (2003) Expert Rev. Anticancer Ther. 3:367-380.
Kim, E.S. et al. (2001) Current Opinion Oncol. 13:506-513.
Knowlden, J. M. (2005) Endocrinology 146(11):4609-4618.
Kopecky, D. J. et al: “Identification and optimization of N <3>, N<6>-diaryl-1H-pyrazolo [3,4-d] pyrimidine-3, 6-diamines as a novel class of ACK1 inhibitors” Bioorganic & Medicinal Chemistry Letters, Pergamon, Elsevier Science, vol. 18, No. 24. Dec. 15, 2008 pp. 6352-6356.
Krishnan, S. et al. (2003) Frontiers in Bioscience 8, e1-13.
Knutsen, L., et al., Journal of the Chemcial Society 1984 vol. 2, pp. 229-238.
Knutsen, L., et al., Journal of the Chemcial Society 1985 pp. 621-630.
Krontiris, T.G., (1994) Internal Medicine 4th Edition, Chapters 71 and 72, pp. 699-729 (Editor is Stein, J.H.).
Kurmasheva, R. T. and Houghton, P. J. (2006) Biochim Biophys Acta 1766:1-22.
Levitzki, A. (2003) Lung Cancer 41 Suppl 1, S9-14.
Li, M. et al. (2002) Clin.Cancer Res. 8:3570-3578.
Liu, B. (2001) Oncogene 20:1913-1922.
Liu, M. et. al. “Synthesis and SAR of 1,9-dihydro-9-hydroxypyraxolo[3,4-b]quinolin-4-ones as novel, selective c-Jun N-terminal kinase inhibitors” Bioorganic & Medicinal Chemistry Letters 2006, 16, 2590-2594.
Lu, D. et al. (2004) J. Biol. Chem. Jan. 23; 279(4): 2856-65.
Lu, Y. et al. (2001) Journal of the National Cancer Institute 93: 1852-1857.
Magne, N. et al. (2002) British Journal of Cancer 86:819-827.
Magne, N. et al. (2003) Clin. Can. Res. 9:4735:4732.
Mahajan, N.P.(2005) Cancer Research 65 (22):10514-10523.
Mahajan, N.P.(2007) PNAS 104 (20): 8438-8443.
Manser, E. et al. (1993) Nature 363 (6427):364-367.
McCarty, M. F. (2004) Integrative Cancer Therapies 3(4): 349-380.
Michelotti, E.L. et. al. “Two classes of p38a MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes” Bioorganic & Medicinal Chemistry Letters 2005, 15, 5274-5279.
Mitchell, W.L. et al. J. Heterocyclic Chem., 1984 vol. 21, No. 3, pp. 697-699.
Miyazaki, Y. et al. “Design and effective synthesis of novel templates, 3,7-diphenyl-4-amino-thieno and furo-[3,2-c] pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases” Bioorganic & Medicinal Chemistry Letters 2007, 17, 250-254.
Morgillo, F. et al. (2006) Cancer Res 66(20):10100-10111.
Mulvihill, M.J. et al: “Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a] pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors” Bioorganic & Medicinal Chemistry, Elsevier Science Ltd. vol. 16, No. 3, Oct. 23, 2007, pp. 1359-1375.
Nahta, R. (2005) Cancer Research 65:11118-111128.
National Library of Medicine—Medical Subject Headings definition of Sarcoma 1999 (http://www.nlm.nih.gov/mesh/2008/MBrowser.html, then type “sarcoma”); last accessed Jul. 1, 2008.
OSI Pharmaceuticals, Inc.:“Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma”, XP-002590463, retrieved from the internet: http://clinicaltrials.gov/show/NCT00924989 (2009).
Pao, W. et al. (2010) Nature Reviews Cancer 10(11) pp. 760-774.
Park, J.O. et al., (2003) Japanese Journal of Clinical Oncology 33 (10) pp. 533-537.
Parrizas, M. et al. (1997) Endocrinology, vol. 138, pp. 1427-1433.
Pink, C.J. et al. (2008) “Organic Solvent Nanofiltration and Absorbents; A Hybrid Approach to Achieve Ultra Low Palladium Contamination of Post Coupling Reaction Products,” Organic Process Research & Development, vol. 12, No. 4, pp. 589-595.
Raben, D. et al. (2002) Semin. Oncol. vol. 29, No. 1, suppl 4 (February): pp. 37-46.
Robertson, D. et al., Imidazole-Pyridine Bioisosterism: Comparison of the Intropis Activities of Pyridine- and Imidazole-Substituted 6-Phenyldihydropyridazinone Cardiotonics. J. Med. Chem. 1988, vol. 31, pp. 461-465.
Roskoski, R., Jr. (2004) Biochem Biophys Res Commun 319:1-11.
Smalley Jr., T. L. et al., Synthesis and evaluation of a novel heterocyclic inhibitors of GSK-3. Bioorganic & Medicinal Letters 16 (2006) 2091-2094.
Seymour, L. (2003) Current Opin. Investig. Drugs 4(6):658-666.
Sharma, S.V., et al., 2007 Nature Reviews|Cancer vol. 7, pp. 169-181.
Snow, R.J. et al. “Hit-to-lead studies on benzimidazole inhibitors of ITK: Discovery of a novel class of kinase inhibitors” Bioorganic & Medicinal Chemistry Letters 2007 17 3660-3665.
Solomon, B. et al (2003) Int. J. Radiat. Oncol. Biol. Phys. 55:713-723.
Steinbach, J. P. et al.(2004) Biochem Biophys Res Commun. Aug. 27;321 (3): 524-30.
Thomas, et al. (1998) Expert Opinion Ther. Pat., vol. 8, pp. 475-478.
Thomson, S., et al., 2005 Cancer Res 65 (20) pp. 9455-9462.
Torrance, C.J. et al. (2000) Nature Med. 6:1024-1028.
Tortora, G. et al. (2003) Clin. Cancer Res. 9:1566-1572.
Valeriote, F. et al. (1975) Cancer Chemotherapy Reports (5):895-900.
Van Der Horst, E.T. et al. (2005) PNAS 102 (44):15901-15906.
International Preliminary Report on Patentability and Written Opinion in PCT/US2010/031547 date of issuance of report Oct. 25, 2011.
ISR and WOSA dated Nov. 7, 2011 PCT/US2011/045807.
Database WPI Week 200529, Derwent Publications Ltd., London, GB; (Apr. 7, 2005) AN 2005-277172.
Abushanab, E. and Lee D.Y. Journal of Organic Chemistry, 1975 vol. 40, No. 23, pp. 3376-3378.
Adachi, Y. et al. (2004) CAS Accession #2005:366557, corresponding to Novartis Foundation Symposium 262 (biology of IGF-1), 177-192.
Akio, M. et al. Machine English Translation of JP 07133280, (1995).
Akio, M.et al. (1995) English Language Abstract of JP 07133280.
Albert, A. et al. (1970) Journal of the Chemical Society, vol. 11, pp. 1540-1547.
Albert, A. et al. (1969) Chem. Biol. Pterdines.Proc.Int.Symp., 4th, 4:1-5.
Almeida, M. Q., et al., (2008) J. Clin. Enocrinol Metab 93 (9), pp. 3524-3531.
Arteaga, C.L. and Johnson, D.H. (2001) Current Opinion Oncol. 13:491-498.
Balak, M.N., et al., (2006) Clinical Cancer Res 12(21) pp. 6494-6501.
Baserga, R. (1999) Exp.Cell.Res, vol. 253, pp. 1-6.
Bertino, J. R. et al. (2000), “Part XIV;Oncology, The Principles of Cancer Therapy” Cecil Textbook of Medicine, Goldman, L. et al., 21st Edition, W.B. Saunders Co., Philadelphia, PA, pp. 1060-1070.
Bevacizumab and Gemcitabine Combined with either Cetuximab or Erlotinib in Treating Patients with Advanced Pancreatic Cancer Internet Citation, [Online] Sep. 7, 2004, XP002410261. Retrieved from the Internet: URL: http://www.clinicaltrials.gov/ct/.
Bhattacharya, B.K. et al. Journal of Heterocyclic Chemistry 1993 pp. 1341-1349.
Blair, J. B. et al., Thieno[3,2-b]- and Thieno[2,3-b]pyrrole Bioisoteric Analogues of the Hallucinogen and Serotonin Agonist N,N-Dimethyltryptamine. J. Chem. Med. 1999, 42, 1106-1111.
Breault, G.A., et al., Cyclin-Dependent Kinase 4 Inhibitors as a Treatment for Cancer. Part 2: Identification and Optimisation of Substitiuted 2,4-Bis Anilino Pyrimidines. Bioorganic & Medicinial Chemistry Letters 13 (2003) 2961-2966.
Brown Eric, et al. (2009) Proceedings of the Annual Meeting of the American Association for Cancer Research; 100th Annual Meeting of the American Assoc. for Cancer Research Denver, CA, USA; Apr. 18-22, 2009 vol. 50 p. 419.
Buck, E., et al., (2008) European Journal of Cancer Supplement vol. 6, No. 12, p. 31.
Bulgaru, A.M. et al. (2003) Expert Rev. Anticancer Ther.3:269-279.
Camirand, A. et al. (2005) Breast Cancer Research 2005, 7:R570-R579.
Chakravarti, A. et al.(2002) Cancer Research 62: 200-207.
Ciardiello, F. et al. (2000) Clin. Cancer Res. 6:2053-2063.
Ciardiello, F. et al. (2003) Clin. Cancer Res. 9:1546-1556.
CLINICALTRIALS.gov, US National Institute of Health: “Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Carcinoma (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene,” OSI Pharmaceuticals XP002677837, retrieved from the Internet: URL:http://clinicaltrials.gov/archive/NCTO 1221077/Feb. 22, 2011.
Contessa, J. N. et al. (1999) Clin. Cancer Res. 5:405-411.
Dancey, J. and Sausville, E.A. (2003) Nature Rev. Drug Discovery 2:296-313.
De Bono, J.S. and Rowinsky, E.K. (2002) Trends in Mol. Medicine 8:S19-S26.
Dineen, et al. “Efficient Transamidation of Primary Carboxamides by in Situ Activation with N, N-Dialkylformamide Dimethyl Acetals” Journal of the American Chemical Society, 2006, 128, 16406-16409.
Dohle, W. et al. “Mild Synthesis of Polyfunctional Benzimidazoles and Indoles by the Reduction of Functionalized Nitroarenes with Phenylmagnesium Chloride” Chemistry a European Journal 2003, 9, 5323-5331.
Dorwald, F.A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface p. 1-15, 41, 279-308.
EJC News (2008) European Journal of Cancer vol. 44, No. 2, pp. 167-171.
Expert Opinion Ther. Pat., (1998) vol. 8, pp. 475-478.
Eyzaguirre, A. et al., Proceedings of the Annual Meeting of the American Association for Cancer Research vol. 50 Apr. 1, 2009 pp. 678-679.
Galisteo, M.L. et al. (2006) PNAS 103 (26): 9796-9801.
Goodman and Gilman, (Tenth Edition 2001) Goodman and Gilman's The Pharmacological Basis of Therapeutics Chapter 1, pp. 3-29.
Grunwald, V. and Hidalgo, M. (2003) J. Nat. Cancer Inst. 95:851-867.
Gundisch, D. et al., Synthesis and Evaluation of Pyridazine and Pyrimidine Containing Bioisoteres of (+)-Pyrido[3.4-b]homotropane and Pyrido-[3.4-b]tropane as Novel nAChR Ligands. Bioorganic & Medicinal Chemistry 10 (2002) 1-9.
Guillory J K Ed—Brittan H G: “Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids ,” Polymorphism in Pharmaceutical Solids (1999) pp. 183-226, XP002376368 Chapters, I, II and III.
Gupta, R.A. and Dubois, R.N. (2000) Nature Med. 6:974-975.
Gura, et al. (1997) Science 278:1041-1042.
Hartz, R. A. et al. (2002) Bioorganic & Medicinal Chemistry Letters, vol. 12, pp. 291-294.
Heim-Riether, A. et al. Journal of Organic Chemistry, 2005 vol. 70, No. 18, pp. 7331-7337.
Herbst, R.S. et al. (2001) Expert Opin. Biol. Ther. 1:719-732.
Holbro, T. and Hynes, N.E. (2004) Annu Rev Pharmacol Toxicol 44:195-217.
Huang, S. et al. (1999) Cancer Res. 59:1935-1940.
Hurbin, A. et al. (2003) Ann. N. Y. Acad. Sci 1010:354-357.
Ji, Qun-sheng, et al., (2007) Mol Cancer Ther 6 (8) pp. 2158-2167.
Jiang, R. et al. “3,5-Disubstituted quinolines as novel c-Jun N-terminal kinase inhibitors.” Bioorganic & Medicinal Chemistry Letters 2007, 17, 6378-6382.
Yang, W. et al. (1999) The Journal of Biological Chemistry 274 (13): 8524-8530.
Yuen, J. SP, et al. (2008) Expert Opinion in Therapeutic Targets 12(5) pp. 589-603.
Zeng, Zhihong et al. (2007) Blood vol. 109, No. 8 pp. 3509-3512.
Ciardiello, F. et al. (2000) Clin. Cancer Res. 6:3739-3747.
Bardel, P., et al. (1994) J. Med. Chem. vol. 37. pp. 4567-4571.
Related Publications (1)
Number Date Country
20120041202 A1 Feb 2012 US
Provisional Applications (1)
Number Date Country
61170911 Apr 2009 US